Human pancreatic cancer-associated stellate cells remain activated after in vivo chemoradiation

M. Carla Cabrera, Estifanos Tilahun, Rebecca Nakles, Edgar S. Diaz-Cruz, Aline Charabaty Pishvaian, Simeng Suy, Patrick Jackson, Lisa Ley, Rebecca Slack, Reena Jha, Sean P. Collins, Nadim Haddad, Bhaskar V.S. Kallakury, Timm Schroeder, Michael J. Pishvaian, Priscilla A. Furth

Research output: Contribution to journalArticle

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive fibrotic reaction or desmoplasia and complex involvement of the surrounding tumor microenvironment. Pancreatic stellate cells are a key mediator of the pancreatic matrix and they promote progression and invasion of pancreatic cancer by increasing cell proliferation and offering protection against therapeutic interventions. Our study utilizes human tumor-derived pancreatic stellate cells (HTPSCs) isolated from fine needle aspirates of pancreatic cancer tissue from patients with locally advanced, unresectable pancreatic adenocarcinoma before and after treatment with full-dose gemcitabine plus concurrent hypo-fractionated stereotactic radiosurgery. We show that HTPSCs survive in vivo chemotherapy and radiotherapy treatment and display a more activated phenotype post-therapy. These data support the idea that stellate cells play an essential role in supporting and promoting pancreatic cancer and further research is needed to develop novel treatments targeting the pancreatic tumor microenvironment.

Original languageEnglish (US)
Article number102
JournalFrontiers in Oncology
Volume4 MAY
DOIs
Publication statusPublished - Jan 1 2014
Externally publishedYes

    Fingerprint

Keywords

  • Chemotherapy
  • Gemcitabine
  • Pancreatic cancer
  • PDAC
  • Radiation
  • Stellate cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this